Stock listing
Stemrim Inc.
Selected listing: SRIMF · OTC · USD · US
Stemrim Inc. (OTC:SRIMF), Commercial Services. Latest release Oct 7, 2026: Notice Regarding US Patent Registration of SR-GT1 for Dystrophic Epidermolysis…
- Ticker
- OTC:SRIMF
- Asset type
- Stock
- Sector
- Commercial Services
- Industry
- Miscellaneous Commercial Services
- Exchange
- OTC
- Currency
- USD
Latest news from Stemrim Inc.
Notice Regarding US Patent Registration of SR-GT1 for Dystrophic Epidermolysis Bullosa
October 7, 2026
Patent Registration in South Korea for Redasemtide in Cartilage Disorders
September 25, 2026
StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees
September 10, 2026
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees
September 9, 2026
StemRIM Announces Patent Registration for SR-GT1 Aimed at Curative Treatment of Dystrophic Epidermolysis Bullosa in South Korea
August 3, 2026